Ticlopidine Interactions

CYP1A2 inhibitor; concomitant use should be avoided due to potential for hypotension, bradycardia, or excessive drowsiness.

Source: NLP:tizanidine

Concomitant use should be avoided due to potential interactions. If clinically necessary, initiate with 2 mg and titrate cautiously.

Source: NLP:tizanidine hydrochloride

Should be avoided due to CYP1A2 inhibition. If necessary, initiate tizanidine at 2 mg and titrate cautiously; monitor for hypotension, bradycardia, or excessive drowsiness.

Source: NLP:tizanidne hydrochloride

CYP2B6 inhibitor that increases bupropion exposure and decreases hydroxybupropion exposure. Dosage adjustment of bupropion may be necessary based on clinical response.

Source: NLP:bupropion hcl er (xl)

CYP2B6 inhibitor that can increase bupropion exposure but decrease hydroxybupropion exposure. Dosage adjustment may be necessary.

Source: NLP:bupropion hydrochloride

CYP3A4 inhibitor that increases carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustment may be required.

Source: NLP:carbamazepine

Strong CYP2C19 inhibitor that may increase exposure to N-desmethylclobazam active metabolite, increasing risk of dose-related adverse reactions.

Source: NLP:clobazam

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Source: NLP:fosphenytoin sodium

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Source: NLP:extended phenytoin sodium

CYP2C19 inhibitor that increases propranolol exposure. Monitor for bradycardia and hypotension.

Source: NLP:propranolol hydrochloride